Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-Blind, Placebo-Controlled, Multicenter Study to Determine the Effectiveness and Tolerability of the Combination of DMP 266 and Indinavir Versus Indinavir in HIV-Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy

NCT00002393 is registered in ClinicalTrials.gov with Dupont Merck as lead sponsor.

NCT NCT00002393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-Blind, Placebo-Controlled, Multicenter Study to Determine the Effectiveness and Tolerability of the Combination of DMP 266 and Indinavir Versus Indinavir in HIV-Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy
Lead sponsor
Dupont Merck
Phase
Phase 3
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
300
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections